The two companies have extended their existing collaboration by a further two years, aiming to develop novel cancer immunotherapies
Oxford BioTherapeutics has extended its second multi-year collaboration with Boehringer Ingelheim for an additional two years. With this extension further programs will be added into the existing collaboration, with the goal to enable the development of novel cancer immunotherapies in areas of high unmet patient need.
The two partnerships between OBT and Boehringer Ingelheim were initiated in April 2013 and October 2020. They are both focused on the discovery of novel tumour targets enabled by OBT’s proprietary OGAP discovery platform for Boehringer Ingelheim’s unique immuno-oncology and ADC platforms, contributing to the company’s aspiration of transforming the lives of people living with cancer with the ultimate goal of curing a range of cancers.
Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “Last month marked the 10-year anniversary of our partnership with Boehringer Ingelheim and it is fitting to mark this anniversary by extending our collaboration both in time and in value. Over the past decade, we have built a successful relationship with Boehringer Ingelheim’s cancer research, now in its third phase, through high-quality outputs enabled by our proprietary OGAP discovery platform. Since 2013, the company has selected three targets discovered using OGAP, of which two programs have led to therapeutic assets in Phase 1 clinical development. We look forward to the next phase of our highly successful partnership and to continuing to work together to develop innovative first-in-class treatments for patients with difficult to treat cancers.”
Over the past decade, we have built a successful relationship with Boehringer Ingelheim’s cancer research
A major differentiator between OBT’s discovery platform and other approaches is the retention of the link between individual patient samples through to the design of therapeutic antibodies and diagnostic patient selection tools, which increases the overall success rate of these novel compounds transitioning into clinical development.
Under the terms of the extended agreement, Boehringer Ingelheim is responsible for the development and commercialisation of treatment candidates that interact with the novel targets identified by OGAP. OBT will receive research funding as well as success-based development and regulatory milestone payments and royalties on potential future product sales.